7-甲基咪唑并[1,2-a]吡啶-2-甲醛 | 202348-54-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 7-甲基咪唑并[1,2-a]吡啶-2-甲醛
• 中文别名: 7-甲基咪唑[1,2-A]吡啶-2-甲醛
• 英文名称: 7-methylimidazo[1,2-a]pyridine-2-carbaldehyde
• CAS: 202348-54-7
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: AETJTTLBDVLRJO-UHFFFAOYSA-N

物化性质

• 密度：
  1.21

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  34.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Methylimidazo[1,2-a]pyridine-2-carbaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Methylimidazo[1,2-a]pyridine-2-carbaldehyde
CAS number: 202348-54-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8N2O
Molecular weight: 160.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-甲基咪唑并[1,2-a]吡啶-2-甲醛 在 indium(III) chloride 、 sodium carbonate 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 12.0h， 生成 N-(tert-butyl)-1-(3,4-dimethoxybenzyl)-3-methylene-2-(7-methylimidazo[1,2-a]pyridin-2-yl)-4-oxoazetidine-2-carboxamide
  参考文献：
  名称：

  通过后 Ugi 亲核环化以多样性为导向合成 β-内酰胺和 γ-内酰胺：路易斯酸作为区域选择性开关

  摘要：

  通过后Ugi InIII催化的分子内加成反应成功合成了杂环稠合α-亚甲基β-内酰胺。从 InCl3 转换为 AlCl3 导致 α,β-不饱和 γ-内酰胺的区域选择性合成。此外，在 Ugi 加合物中用取代的炔烃取代末端炔烃导致两种催化体系均形成 γ-内酰胺。

  DOI：

  10.1002/ejoc.201500270
• 作为产物：
  描述：

  2-氨基-4-甲基吡啶 在 calcium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 5.0h， 生成 7-甲基咪唑并[1,2-a]吡啶-2-甲醛
  参考文献：
  名称：

  通过后 Ugi 亲核环化以多样性为导向合成 β-内酰胺和 γ-内酰胺：路易斯酸作为区域选择性开关

  摘要：

  通过后Ugi InIII催化的分子内加成反应成功合成了杂环稠合α-亚甲基β-内酰胺。从 InCl3 转换为 AlCl3 导致 α,β-不饱和 γ-内酰胺的区域选择性合成。此外，在 Ugi 加合物中用取代的炔烃取代末端炔烃导致两种催化体系均形成 γ-内酰胺。

  DOI：

  10.1002/ejoc.201500270

文献信息

• [EN] VIRAL REPLICATION INHIBITORS<br/>[FR] INHIBITEURS DE REPLICATION VIRALE
  申请人：UNIV LEUVEN KATH

  公开号：WO2013045516A1

  公开（公告）日：2013-04-04

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，通过使用这些新化合物来预防或治疗动物的病毒感染的方法，以及将这些新化合物用作药物，更好地用于治疗或预防病毒感染，特别是感染RNA病毒，更特别是感染属于黄病毒科的病毒，更特别是感染登革病毒。本发明还涉及这些新化合物的药物组合或混合制剂，用作药物的组合或制剂，更好地用于预防或治疗病毒感染。该发明还涉及这些化合物的制备方法。
• Chemical Compounds
  申请人：Gudmundsson Kristjan

  公开号：US20080171740A1

  公开（公告）日：2008-07-17

  The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to a chemokine receptor, and which affect the binding of a natural ligand or chemokine to a receptor, such as CXCR4 of a target cell.

  本发明提供了一种新型化合物，它们以与趋化因子受体结合的方式对目标细胞表现出保护效应，并影响天然配体或趋化因子与目标细胞的受体（如CXCR4）的结合。
• VIRAL REPLICATION INHIBITORS
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

  公开号：US20140213586A1

  公开（公告）日：2014-07-31

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，使用这些新化合物预防或治疗动物的病毒感染的方法，以及这些新化合物的药物用途，更好地用于治疗或预防病毒感染，特别是RNA病毒感染，更特别是属于黄病毒科的病毒感染，更进一步地是登革热病毒感染。本发明还涉及新化合物的药物组成物或复合制剂，以及用于预防或治疗病毒感染的药物组成物或制剂。本发明还涉及化合物的制备方法。
• Viral replication inhibitors
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. Leuven R&D

  公开号：US10550123B2

  公开（公告）日：2020-02-04

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新型化合物、使用这些新型化合物预防或治疗动物病毒感染的方法以及用作药物的所述新型化合物，更优选用作治疗或预防病毒感染的药物，特别是 RNA 病毒感染，更特别是属于黄病毒科的病毒感染，更特别是登革热病毒感染。本发明还涉及新型化合物的药物组合物或组合制剂、用作药物的组合物或制剂，更优选用于预防或治疗病毒感染。本发明还涉及化合物的制备工艺。
• 含氮大环类化合物及其制备方法和医药用途
  申请人：[en]THE NATIONAL INSTITUTES OF PHARMACEUTICAL R & D CO., LTD;[zh]中国医药研究开发中心有限公司

  公开号：WO2024046512A2

  公开（公告）日：2024-03-07

  本发明涉及含氮大环类化合物及其制备方法和医药用途。具体地，本发明涉及通式(I)所示的含氮大环类化合物，其制备方法，含有其的药物组合物，以及其作为ALK激酶抑制剂，用于治疗与ALK激酶活性相关的疾病的用途。其中通式(I)中的各基团的定义与说明书中的定义相同。